Plenty of folks have been using GLP-1s — generic versions of popular weight loss drugs such as Ozempic and Zepbound — to jump ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.

Weight loss drugs have surged in popularity. But Gov. Ned Lamont wants CT’s Medicaid program to discontinue covering them for ...

A coalition of over 20 leading health organizations is calling on the U.S. Food & Drug Administration (FDA) to enforce ...

A coalition of over 20 leading health organizations is calling on the U.S. Food & Drug Administration (FDA) to enforce ...

Early adopters of GLP-1 drugs have now lost the weight and are beginning to transition off them. How can F&B support the ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

US pharmaceutical company Eli Lilly has launched Mounjaro, a diabetes and weight-loss drug, in India. Priced at Rs 3,500 for a 2.5 mg vial, the ‘game-changing’ medication has debuted in the Indian ...

The following is a summary of “Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists,” ...

Eli Lilly’s Mounjaro has launched in India. Approved by CDSCO, it promises significant weight loss and blood sugar control. However, concerns remain over certain side effects.

Eli Lilly launched Mounjaro, a weight-loss injectable, in India, priced at ₹4,375 for 5 mg, targeting obesity and type-2 diabetes management.

Dose expansion in Phase 1 CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML) expected to initiate in 2Q25 with additional safety and ...